JP2019502684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502684A5 JP2019502684A5 JP2018531122A JP2018531122A JP2019502684A5 JP 2019502684 A5 JP2019502684 A5 JP 2019502684A5 JP 2018531122 A JP2018531122 A JP 2018531122A JP 2018531122 A JP2018531122 A JP 2018531122A JP 2019502684 A5 JP2019502684 A5 JP 2019502684A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- amino acid
- terminal lysine
- acid residue
- conjugated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims description 165
- 102000018358 immunoglobulin Human genes 0.000 claims description 165
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 118
- 239000004472 Lysine Substances 0.000 claims description 118
- 235000018977 lysine Nutrition 0.000 claims description 118
- 125000000539 amino acid group Chemical group 0.000 claims description 114
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 110
- 210000004899 c-terminal region Anatomy 0.000 claims description 109
- 125000002252 acyl group Chemical group 0.000 claims description 50
- 239000000758 substrate Substances 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 47
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 43
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 26
- 235000004554 glutamine Nutrition 0.000 claims description 26
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 26
- 229960002743 glutamine Drugs 0.000 claims description 26
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 22
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 22
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 22
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 22
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 22
- 229960005261 aspartic acid Drugs 0.000 claims description 22
- 235000003704 aspartic acid Nutrition 0.000 claims description 22
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 22
- 235000013922 glutamic acid Nutrition 0.000 claims description 22
- 229960002989 glutamic acid Drugs 0.000 claims description 22
- 239000004220 glutamic acid Substances 0.000 claims description 22
- 229960002429 proline Drugs 0.000 claims description 22
- 235000013930 proline Nutrition 0.000 claims description 22
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 20
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 20
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 20
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 20
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 20
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 20
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 20
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 20
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 20
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 20
- 239000004473 Threonine Substances 0.000 claims description 20
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 20
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 20
- 229960003767 alanine Drugs 0.000 claims description 20
- 235000004279 alanine Nutrition 0.000 claims description 20
- 229960001230 asparagine Drugs 0.000 claims description 20
- 235000009582 asparagine Nutrition 0.000 claims description 20
- 229960002433 cysteine Drugs 0.000 claims description 20
- 235000018417 cysteine Nutrition 0.000 claims description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 20
- 229960002885 histidine Drugs 0.000 claims description 20
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 20
- 235000014304 histidine Nutrition 0.000 claims description 20
- 229960000310 isoleucine Drugs 0.000 claims description 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 20
- 235000014705 isoleucine Nutrition 0.000 claims description 20
- 229960003136 leucine Drugs 0.000 claims description 20
- 235000005772 leucine Nutrition 0.000 claims description 20
- 229930182817 methionine Natural products 0.000 claims description 20
- 229960004452 methionine Drugs 0.000 claims description 20
- 235000006109 methionine Nutrition 0.000 claims description 20
- 229960005190 phenylalanine Drugs 0.000 claims description 20
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 20
- 235000008729 phenylalanine Nutrition 0.000 claims description 20
- 229960001153 serine Drugs 0.000 claims description 20
- 235000004400 serine Nutrition 0.000 claims description 20
- 229960002898 threonine Drugs 0.000 claims description 20
- 235000008521 threonine Nutrition 0.000 claims description 20
- 229960004799 tryptophan Drugs 0.000 claims description 20
- 229960004441 tyrosine Drugs 0.000 claims description 20
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 20
- 235000002374 tyrosine Nutrition 0.000 claims description 20
- 229960004295 valine Drugs 0.000 claims description 20
- 239000004474 valine Substances 0.000 claims description 20
- 235000014393 valine Nutrition 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 239000004471 Glycine Substances 0.000 claims description 16
- 229960002449 glycine Drugs 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 14
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 12
- 108060008539 Transglutaminase Proteins 0.000 claims description 12
- 230000000813 microbial effect Effects 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 12
- 102000003601 transglutaminase Human genes 0.000 claims description 12
- 239000000032 diagnostic agent Substances 0.000 claims description 11
- 229940039227 diagnostic agent Drugs 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- -1 carboxylbenzyloxy (CBZ) group Chemical group 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 125000003827 glycol group Chemical group 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 5
- 235000009697 arginine Nutrition 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960003121 arginine Drugs 0.000 claims description 5
- 230000001268 conjugating effect Effects 0.000 claims description 4
- 230000021615 conjugation Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 3
- 229960003646 lysine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 241001495137 Streptomyces mobaraensis Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 description 4
- SHDPRTQPPWIEJG-UHFFFAOYSA-N 1-methylcyclopropene Chemical compound CC1=CC1 SHDPRTQPPWIEJG-UHFFFAOYSA-N 0.000 description 2
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 2
- NSVXZMGWYBICRW-ULKQDVFKSA-N [(1s,8r)-9-bicyclo[6.1.0]non-4-ynyl]methanol Chemical group C1CC#CCC[C@@H]2C(CO)[C@@H]21 NSVXZMGWYBICRW-ULKQDVFKSA-N 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021176196A JP2022023181A (ja) | 2015-12-18 | 2021-10-28 | Ｃ末端リジンで結合体化された免疫グロブリン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269138P | 2015-12-18 | 2015-12-18 | |
| US62/269,138 | 2015-12-18 | ||
| PCT/US2016/067165 WO2017106643A1 (en) | 2015-12-18 | 2016-12-16 | C-terminal lysine conjugated immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021176196A Division JP2022023181A (ja) | 2015-12-18 | 2021-10-28 | Ｃ末端リジンで結合体化された免疫グロブリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502684A JP2019502684A (ja) | 2019-01-31 |
| JP2019502684A5 true JP2019502684A5 (enExample) | 2020-01-30 |
| JP6970090B2 JP6970090B2 (ja) | 2021-11-24 |
Family
ID=57960810
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531122A Active JP6970090B2 (ja) | 2015-12-18 | 2016-12-16 | Ｃ末端リジンで結合体化された免疫グロブリン |
| JP2021176196A Pending JP2022023181A (ja) | 2015-12-18 | 2021-10-28 | Ｃ末端リジンで結合体化された免疫グロブリン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021176196A Pending JP2022023181A (ja) | 2015-12-18 | 2021-10-28 | Ｃ末端リジンで結合体化された免疫グロブリン |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11135304B2 (enExample) |
| EP (2) | EP3390440B1 (enExample) |
| JP (2) | JP6970090B2 (enExample) |
| KR (1) | KR102728631B1 (enExample) |
| CN (1) | CN108602878B (enExample) |
| AU (1) | AU2016369524B2 (enExample) |
| BR (1) | BR112018012388A2 (enExample) |
| CL (1) | CL2018001565A1 (enExample) |
| CO (1) | CO2018005876A2 (enExample) |
| ES (1) | ES2910699T3 (enExample) |
| IL (1) | IL259754B (enExample) |
| MA (1) | MA44074A (enExample) |
| MX (1) | MX2018007451A (enExample) |
| MY (1) | MY192987A (enExample) |
| NZ (1) | NZ742916A (enExample) |
| PH (1) | PH12018501272A1 (enExample) |
| RU (1) | RU2747581C2 (enExample) |
| SG (1) | SG11201804856VA (enExample) |
| UA (1) | UA124622C2 (enExample) |
| WO (1) | WO2017106643A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2994741A1 (en) * | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| ES2910699T3 (es) | 2015-12-18 | 2022-05-13 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas con lisina C-terminal |
| LT3464336T (lt) | 2016-06-01 | 2022-05-10 | Athira Pharma, Inc. | Junginiai |
| CA3026991A1 (en) | 2016-06-10 | 2017-12-14 | Eisai R&D Management Co., Ltd. | Lysine conjugated immunoglobulins |
| EP3272864A1 (en) * | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| KR20240046307A (ko) | 2017-04-28 | 2024-04-08 | 아지노모토 가부시키가이샤 | 가용성 단백질에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염 |
| WO2019035681A2 (ko) | 2017-08-17 | 2019-02-21 | 주식회사 엘지화학 | 전고체 전지용 전극 및 그 제조방법 |
| NZ762376A (en) | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| AU2019316103B2 (en) | 2018-08-02 | 2026-02-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20210324101A1 (en) * | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP7657213B2 (ja) | 2019-11-07 | 2025-04-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 |
| TWI901692B (zh) | 2020-06-05 | 2025-10-21 | 日商衛材R&D企管股份有限公司 | 抗ｂｃｍａ抗體-藥物軛合物及其使用方法 |
| PE20231512A1 (es) | 2020-10-25 | 2023-09-26 | Araris Biotech Ag | Medios y metodos para producir conjugados de ligador-anticuerpo |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN120813607A (zh) | 2023-02-28 | 2025-10-17 | 卫材R&D管理有限公司 | 抗psma抗体、缀合物和使用方法 |
| WO2025198987A1 (en) * | 2024-03-21 | 2025-09-25 | Merck Sharp & Dohme Llc | Polypeptides for bioconjugation |
| WO2025199464A1 (en) | 2024-03-22 | 2025-09-25 | Eisai R&D Management Co., Ltd. | Anti-trop2 antibody-drug conjugates and methods of use |
| CN120779021A (zh) * | 2024-04-08 | 2025-10-14 | 菲鹏生物股份有限公司 | 抗体缀合物及其用途 |
| WO2026044039A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Anti-cd73 antibodies, conjugates, and methods of use |
| WO2026044149A2 (en) | 2024-08-21 | 2026-02-26 | Eisai R&D Management Co., Ltd. | Synthesis of drug-linker combinations for antibody-drug conjugates |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| EP2368579A1 (en) * | 2004-01-21 | 2011-09-28 | Novo Nordisk Health Care AG | Transglutaminase mediated conjugation of peptides |
| AT503902B1 (de) * | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| US8426179B2 (en) * | 2007-08-30 | 2013-04-23 | Northwestern University | Synthetic peptide and peptide conjugates and related tissue coupling methods via transglutaminase enzyme |
| CA2698541C (en) * | 2007-10-19 | 2018-01-09 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013176516A1 (ko) | 2012-05-24 | 2013-11-28 | 한화케미칼 주식회사 | 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도 |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| KR20160040556A (ko) * | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
| US9608508B2 (en) * | 2013-07-29 | 2017-03-28 | Microsemi P.O.E Ltd. | Integrated limiter and active filter |
| WO2015015448A2 (en) * | 2013-07-31 | 2015-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates |
| US11602525B2 (en) * | 2014-04-25 | 2023-03-14 | Rinat Neuroscience Corp. | Antibody-drug conjugates with high drug loading |
| ES2910699T3 (es) * | 2015-12-18 | 2022-05-13 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas con lisina C-terminal |
| CA3026991A1 (en) | 2016-06-10 | 2017-12-14 | Eisai R&D Management Co., Ltd. | Lysine conjugated immunoglobulins |
-
2016
- 2016-12-16 ES ES16834067T patent/ES2910699T3/es active Active
- 2016-12-16 EP EP16834067.7A patent/EP3390440B1/en active Active
- 2016-12-16 BR BR112018012388-9A patent/BR112018012388A2/pt active Search and Examination
- 2016-12-16 CN CN201680074660.1A patent/CN108602878B/zh active Active
- 2016-12-16 MY MYPI2018000867A patent/MY192987A/en unknown
- 2016-12-16 SG SG11201804856VA patent/SG11201804856VA/en unknown
- 2016-12-16 AU AU2016369524A patent/AU2016369524B2/en active Active
- 2016-12-16 EP EP22153314.4A patent/EP4032902A1/en not_active Withdrawn
- 2016-12-16 RU RU2018126304A patent/RU2747581C2/ru active
- 2016-12-16 NZ NZ742916A patent/NZ742916A/en unknown
- 2016-12-16 US US16/062,831 patent/US11135304B2/en active Active
- 2016-12-16 IL IL259754A patent/IL259754B/en unknown
- 2016-12-16 UA UAA201807950A patent/UA124622C2/uk unknown
- 2016-12-16 KR KR1020187020064A patent/KR102728631B1/ko active Active
- 2016-12-16 MX MX2018007451A patent/MX2018007451A/es unknown
- 2016-12-16 JP JP2018531122A patent/JP6970090B2/ja active Active
- 2016-12-16 WO PCT/US2016/067165 patent/WO2017106643A1/en not_active Ceased
- 2016-12-16 MA MA044074A patent/MA44074A/fr unknown
-
2018
- 2018-06-07 CO CONC2018/0005876A patent/CO2018005876A2/es unknown
- 2018-06-12 CL CL2018001565A patent/CL2018001565A1/es unknown
- 2018-06-14 PH PH12018501272A patent/PH12018501272A1/en unknown
-
2021
- 2021-08-20 US US17/408,003 patent/US12214050B2/en active Active
- 2021-10-28 JP JP2021176196A patent/JP2022023181A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502684A5 (enExample) | ||
| JP2019525897A5 (enExample) | ||
| RU2018126304A (ru) | Конъюгированные иммуноглобулины с c-концевым лизином | |
| JP7360377B2 (ja) | アントラサイクリン誘導体を含む、結合タンパク質薬物複合体（Ｂｉｎｄｉｎｇ ｐｒｏｔｅｉｎ ｄｒｕｇ ｃｏｎｊｕｇａｔｅｓ） | |
| CN113423735B (zh) | 抗-紧密连接蛋白抗体及其用途 | |
| RU2018145507A (ru) | Конъюгированные с лизином иммуноглобулины | |
| TWI537285B (zh) | 抗-ｎｋｇ２ａ抗體與其用途 | |
| JP7339291B2 (ja) | シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体 | |
| BR112015023589B1 (pt) | Método para a produção de um conjugado de imunoligante/carga útil | |
| TR201809636T4 (tr) | Antikor-ilaç konjugatı. | |
| CN110799537A (zh) | 抗pd-1抗体及其制备和使用方法 | |
| JP2024023249A (ja) | 抗ｐｄ－ｌ１抗体とその作製及び使用方法 | |
| JP2022513686A (ja) | グルタミンを含有する軽鎖ｃ末端に伸長部分を含む抗体およびそのコンジュゲートならびにその方法および用途 | |
| EP4501945A1 (en) | Cleavable fragment directed by affinity fragment, design and synthesis thereof, and use thereof in preparation of site-directed drug conjugate | |
| US20230218778A1 (en) | Para-amino-benzyl linkers, process for their preparation and their use in conjugates | |
| TW202146454A (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| CA3008645C (en) | C-terminal lysine conjugated immunoglobulins | |
| WO2021141996A1 (en) | Single- and multi-chain polypeptides that bind specifically to cd3 epsilon | |
| Feng | One-Bead One-Compound Combinatorial Technology as Enabling Tool for Site-Specific Derivatization of Immunoglobulins | |
| RU2022115696A (ru) | Селективное сульфирование производных бензодиазепина |